cxcl10 Search Results


94
R&D Systems protein 10
Protein 10, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein 10/product/R&D Systems
Average 94 stars, based on 1 article reviews
protein 10 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
MedChemExpress human cxcl10
Human Cxcl10, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cxcl10/product/MedChemExpress
Average 93 stars, based on 1 article reviews
human cxcl10 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
R&D Systems cxcl10 agonist
Fig. 3. (A, B) qRT-PCR and Western blot analysis of <t>CXCL10</t> and CXCR3 expression in HAECs treated with different concentrations of Hcy. (C) IHC analysis of the aorta in HHcy mice showing CXCL10 and CXCR3 expression. (D) qRT-PCR analysis of CXCL10 and CXCR3 expression in arterial endothelial cells.
Cxcl10 Agonist, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cxcl10 agonist/product/R&D Systems
Average 94 stars, based on 1 article reviews
cxcl10 agonist - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

99
Thermo Fisher gene exp cxcl10 mm00445235 m1
Fig. 3. (A, B) qRT-PCR and Western blot analysis of <t>CXCL10</t> and CXCR3 expression in HAECs treated with different concentrations of Hcy. (C) IHC analysis of the aorta in HHcy mice showing CXCL10 and CXCR3 expression. (D) qRT-PCR analysis of CXCL10 and CXCR3 expression in arterial endothelial cells.
Gene Exp Cxcl10 Mm00445235 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp cxcl10 mm00445235 m1/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
gene exp cxcl10 mm00445235 m1 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Thermo Fisher gene exp cxcl10 hs00171042 m1
Fig. 3. (A, B) qRT-PCR and Western blot analysis of <t>CXCL10</t> and CXCR3 expression in HAECs treated with different concentrations of Hcy. (C) IHC analysis of the aorta in HHcy mice showing CXCL10 and CXCR3 expression. (D) qRT-PCR analysis of CXCL10 and CXCR3 expression in arterial endothelial cells.
Gene Exp Cxcl10 Hs00171042 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp cxcl10 hs00171042 m1/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
gene exp cxcl10 hs00171042 m1 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

98
Thermo Fisher gene exp cxcl10 mm99999072 m1
Fig. 3. (A, B) qRT-PCR and Western blot analysis of <t>CXCL10</t> and CXCR3 expression in HAECs treated with different concentrations of Hcy. (C) IHC analysis of the aorta in HHcy mice showing CXCL10 and CXCR3 expression. (D) qRT-PCR analysis of CXCL10 and CXCR3 expression in arterial endothelial cells.
Gene Exp Cxcl10 Mm99999072 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp cxcl10 mm99999072 m1/product/Thermo Fisher
Average 98 stars, based on 1 article reviews
gene exp cxcl10 mm99999072 m1 - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier

96
R&D Systems mouse cxcl10 duoset elisa kit
A. Log 2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from uninjected wild-type, aGR1-treated, and TSLPR -/- animals. B. Log 2 fold change (Day 8 MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. C. Log 2 fold change (Day 8 MC903 vs. EtOH) of activity-induced genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. D. Log 2 fold change (Day 8 MC903 vs. EtOH) of Lcn2 and activity-induced genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. For Figure 4A-D , exact values and corrected p -values are reported in Supplemental Data. E. Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as determined from BTIII staining ( p = 0.8985; two-tailed t-test ( t =0.1294; df =18); n = 9,11 images each from 2 mice per treatment. Exact values are reported in Figure 4-source data 1 . F. <t>CXCL10</t> levels in skin homogenate as measured by ELISA on day 8 of the MC903 model for uninjected animals (left; * p = 0.029 ( t =2.715, df =7); two-tailed t-test; n = 4,5 animals), animals which received aGr1 for 8 days (middle; p = 0.43 ( t =0.815, df =11); two-tailed t-test; n = 6,6 animals), and TSLPR -/- animals (right; * p = 0.0357 ( t =2.696, df =6); two-tailed t-test; n = 4,4 animals. Skin homogenates were isolated on separate days and so uninjected, WT samples were not compared to aGr1-treated samples or to TSLPR -/- samples. G. (Left) Time spent scratching over a thirty minute interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back); (two-way ANOVA: **** p treatment < 0.0001, F(1,67) = 50.64; Tukey’s multiple comparisons: * p day 5 = 0.0216, n=8,10 mice; *** p day 8 = 0.0007, n=18,21 mice; **** p day 12 < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back), and immediately after mice were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 ( t =0.0964, df =8); two-tailed t-test; n = 5,5 mice. Values from bar plots in Figures 4F-G are displayed in Figure 4-source data 2 .
Mouse Cxcl10 Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse cxcl10 duoset elisa kit/product/R&D Systems
Average 96 stars, based on 1 article reviews
mouse cxcl10 duoset elisa kit - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

93
R&D Systems rmcxcl10
A. Log 2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from uninjected wild-type, aGR1-treated, and TSLPR -/- animals. B. Log 2 fold change (Day 8 MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. C. Log 2 fold change (Day 8 MC903 vs. EtOH) of activity-induced genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. D. Log 2 fold change (Day 8 MC903 vs. EtOH) of Lcn2 and activity-induced genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. For Figure 4A-D , exact values and corrected p -values are reported in Supplemental Data. E. Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as determined from BTIII staining ( p = 0.8985; two-tailed t-test ( t =0.1294; df =18); n = 9,11 images each from 2 mice per treatment. Exact values are reported in Figure 4-source data 1 . F. <t>CXCL10</t> levels in skin homogenate as measured by ELISA on day 8 of the MC903 model for uninjected animals (left; * p = 0.029 ( t =2.715, df =7); two-tailed t-test; n = 4,5 animals), animals which received aGr1 for 8 days (middle; p = 0.43 ( t =0.815, df =11); two-tailed t-test; n = 6,6 animals), and TSLPR -/- animals (right; * p = 0.0357 ( t =2.696, df =6); two-tailed t-test; n = 4,4 animals. Skin homogenates were isolated on separate days and so uninjected, WT samples were not compared to aGr1-treated samples or to TSLPR -/- samples. G. (Left) Time spent scratching over a thirty minute interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back); (two-way ANOVA: **** p treatment < 0.0001, F(1,67) = 50.64; Tukey’s multiple comparisons: * p day 5 = 0.0216, n=8,10 mice; *** p day 8 = 0.0007, n=18,21 mice; **** p day 12 < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back), and immediately after mice were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 ( t =0.0964, df =8); two-tailed t-test; n = 5,5 mice. Values from bar plots in Figures 4F-G are displayed in Figure 4-source data 2 .
Rmcxcl10, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rmcxcl10/product/R&D Systems
Average 93 stars, based on 1 article reviews
rmcxcl10 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

86
Thermo Fisher gene exp cxcl10 rh02788358 m1
A. Log 2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from uninjected wild-type, aGR1-treated, and TSLPR -/- animals. B. Log 2 fold change (Day 8 MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. C. Log 2 fold change (Day 8 MC903 vs. EtOH) of activity-induced genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. D. Log 2 fold change (Day 8 MC903 vs. EtOH) of Lcn2 and activity-induced genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. For Figure 4A-D , exact values and corrected p -values are reported in Supplemental Data. E. Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as determined from BTIII staining ( p = 0.8985; two-tailed t-test ( t =0.1294; df =18); n = 9,11 images each from 2 mice per treatment. Exact values are reported in Figure 4-source data 1 . F. <t>CXCL10</t> levels in skin homogenate as measured by ELISA on day 8 of the MC903 model for uninjected animals (left; * p = 0.029 ( t =2.715, df =7); two-tailed t-test; n = 4,5 animals), animals which received aGr1 for 8 days (middle; p = 0.43 ( t =0.815, df =11); two-tailed t-test; n = 6,6 animals), and TSLPR -/- animals (right; * p = 0.0357 ( t =2.696, df =6); two-tailed t-test; n = 4,4 animals. Skin homogenates were isolated on separate days and so uninjected, WT samples were not compared to aGr1-treated samples or to TSLPR -/- samples. G. (Left) Time spent scratching over a thirty minute interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back); (two-way ANOVA: **** p treatment < 0.0001, F(1,67) = 50.64; Tukey’s multiple comparisons: * p day 5 = 0.0216, n=8,10 mice; *** p day 8 = 0.0007, n=18,21 mice; **** p day 12 < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back), and immediately after mice were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 ( t =0.0964, df =8); two-tailed t-test; n = 5,5 mice. Values from bar plots in Figures 4F-G are displayed in Figure 4-source data 2 .
Gene Exp Cxcl10 Rh02788358 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp cxcl10 rh02788358 m1/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
gene exp cxcl10 rh02788358 m1 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier

96
R&D Systems human cxcl10 ip 10 quantikine elisa kit
A. Log 2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from uninjected wild-type, aGR1-treated, and TSLPR -/- animals. B. Log 2 fold change (Day 8 MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. C. Log 2 fold change (Day 8 MC903 vs. EtOH) of activity-induced genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. D. Log 2 fold change (Day 8 MC903 vs. EtOH) of Lcn2 and activity-induced genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. For Figure 4A-D , exact values and corrected p -values are reported in Supplemental Data. E. Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as determined from BTIII staining ( p = 0.8985; two-tailed t-test ( t =0.1294; df =18); n = 9,11 images each from 2 mice per treatment. Exact values are reported in Figure 4-source data 1 . F. <t>CXCL10</t> levels in skin homogenate as measured by ELISA on day 8 of the MC903 model for uninjected animals (left; * p = 0.029 ( t =2.715, df =7); two-tailed t-test; n = 4,5 animals), animals which received aGr1 for 8 days (middle; p = 0.43 ( t =0.815, df =11); two-tailed t-test; n = 6,6 animals), and TSLPR -/- animals (right; * p = 0.0357 ( t =2.696, df =6); two-tailed t-test; n = 4,4 animals. Skin homogenates were isolated on separate days and so uninjected, WT samples were not compared to aGr1-treated samples or to TSLPR -/- samples. G. (Left) Time spent scratching over a thirty minute interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back); (two-way ANOVA: **** p treatment < 0.0001, F(1,67) = 50.64; Tukey’s multiple comparisons: * p day 5 = 0.0216, n=8,10 mice; *** p day 8 = 0.0007, n=18,21 mice; **** p day 12 < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back), and immediately after mice were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 ( t =0.0964, df =8); two-tailed t-test; n = 5,5 mice. Values from bar plots in Figures 4F-G are displayed in Figure 4-source data 2 .
Human Cxcl10 Ip 10 Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cxcl10 ip 10 quantikine elisa kit/product/R&D Systems
Average 96 stars, based on 1 article reviews
human cxcl10 ip 10 quantikine elisa kit - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

94
R&D Systems recombinant mouse cxcl10 protein
A. Log 2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from uninjected wild-type, aGR1-treated, and TSLPR -/- animals. B. Log 2 fold change (Day 8 MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. C. Log 2 fold change (Day 8 MC903 vs. EtOH) of activity-induced genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. D. Log 2 fold change (Day 8 MC903 vs. EtOH) of Lcn2 and activity-induced genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. For Figure 4A-D , exact values and corrected p -values are reported in Supplemental Data. E. Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as determined from BTIII staining ( p = 0.8985; two-tailed t-test ( t =0.1294; df =18); n = 9,11 images each from 2 mice per treatment. Exact values are reported in Figure 4-source data 1 . F. <t>CXCL10</t> levels in skin homogenate as measured by ELISA on day 8 of the MC903 model for uninjected animals (left; * p = 0.029 ( t =2.715, df =7); two-tailed t-test; n = 4,5 animals), animals which received aGr1 for 8 days (middle; p = 0.43 ( t =0.815, df =11); two-tailed t-test; n = 6,6 animals), and TSLPR -/- animals (right; * p = 0.0357 ( t =2.696, df =6); two-tailed t-test; n = 4,4 animals. Skin homogenates were isolated on separate days and so uninjected, WT samples were not compared to aGr1-treated samples or to TSLPR -/- samples. G. (Left) Time spent scratching over a thirty minute interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back); (two-way ANOVA: **** p treatment < 0.0001, F(1,67) = 50.64; Tukey’s multiple comparisons: * p day 5 = 0.0216, n=8,10 mice; *** p day 8 = 0.0007, n=18,21 mice; **** p day 12 < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back), and immediately after mice were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 ( t =0.0964, df =8); two-tailed t-test; n = 5,5 mice. Values from bar plots in Figures 4F-G are displayed in Figure 4-source data 2 .
Recombinant Mouse Cxcl10 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse cxcl10 protein/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant mouse cxcl10 protein - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Fig. 3. (A, B) qRT-PCR and Western blot analysis of CXCL10 and CXCR3 expression in HAECs treated with different concentrations of Hcy. (C) IHC analysis of the aorta in HHcy mice showing CXCL10 and CXCR3 expression. (D) qRT-PCR analysis of CXCL10 and CXCR3 expression in arterial endothelial cells.

Journal: Cellular and molecular biology (Noisy-le-Grand, France)

Article Title: Homocysteine modulates CXCL10/CXCR3 axis activity to induce endothelial dysfunction.

doi: 10.14715/cmb/2024.70.2.28

Figure Lengend Snippet: Fig. 3. (A, B) qRT-PCR and Western blot analysis of CXCL10 and CXCR3 expression in HAECs treated with different concentrations of Hcy. (C) IHC analysis of the aorta in HHcy mice showing CXCL10 and CXCR3 expression. (D) qRT-PCR analysis of CXCL10 and CXCR3 expression in arterial endothelial cells.

Article Snippet: Additionally, HAECs were exposed to specific agents including Anti-CXCL10 antibodies (701225, Invitrogen, USA), Anti-CXCR3 antibodies (ab71864, Abcam, UK), IgG control antibodies (31154, Thermo Fisher, USA), NBI-74330 (a CXCR3 inhibitor, 4528, Tocris Bioscience, UK), and CXCL10 agonist (266-IP, R&D Systems, USA).

Techniques: Quantitative RT-PCR, Western Blot, Expressing

A. Log 2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from uninjected wild-type, aGR1-treated, and TSLPR -/- animals. B. Log 2 fold change (Day 8 MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. C. Log 2 fold change (Day 8 MC903 vs. EtOH) of activity-induced genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. D. Log 2 fold change (Day 8 MC903 vs. EtOH) of Lcn2 and activity-induced genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. For Figure 4A-D , exact values and corrected p -values are reported in Supplemental Data. E. Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as determined from BTIII staining ( p = 0.8985; two-tailed t-test ( t =0.1294; df =18); n = 9,11 images each from 2 mice per treatment. Exact values are reported in Figure 4-source data 1 . F. CXCL10 levels in skin homogenate as measured by ELISA on day 8 of the MC903 model for uninjected animals (left; * p = 0.029 ( t =2.715, df =7); two-tailed t-test; n = 4,5 animals), animals which received aGr1 for 8 days (middle; p = 0.43 ( t =0.815, df =11); two-tailed t-test; n = 6,6 animals), and TSLPR -/- animals (right; * p = 0.0357 ( t =2.696, df =6); two-tailed t-test; n = 4,4 animals. Skin homogenates were isolated on separate days and so uninjected, WT samples were not compared to aGr1-treated samples or to TSLPR -/- samples. G. (Left) Time spent scratching over a thirty minute interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back); (two-way ANOVA: **** p treatment < 0.0001, F(1,67) = 50.64; Tukey’s multiple comparisons: * p day 5 = 0.0216, n=8,10 mice; *** p day 8 = 0.0007, n=18,21 mice; **** p day 12 < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back), and immediately after mice were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 ( t =0.0964, df =8); two-tailed t-test; n = 5,5 mice. Values from bar plots in Figures 4F-G are displayed in Figure 4-source data 2 .

Journal: bioRxiv

Article Title: Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis

doi: 10.1101/653873

Figure Lengend Snippet: A. Log 2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from uninjected wild-type, aGR1-treated, and TSLPR -/- animals. B. Log 2 fold change (Day 8 MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. C. Log 2 fold change (Day 8 MC903 vs. EtOH) of activity-induced genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR -/- animals. D. Log 2 fold change (Day 8 MC903 vs. EtOH) of Lcn2 and activity-induced genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. For Figure 4A-D , exact values and corrected p -values are reported in Supplemental Data. E. Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as determined from BTIII staining ( p = 0.8985; two-tailed t-test ( t =0.1294; df =18); n = 9,11 images each from 2 mice per treatment. Exact values are reported in Figure 4-source data 1 . F. CXCL10 levels in skin homogenate as measured by ELISA on day 8 of the MC903 model for uninjected animals (left; * p = 0.029 ( t =2.715, df =7); two-tailed t-test; n = 4,5 animals), animals which received aGr1 for 8 days (middle; p = 0.43 ( t =0.815, df =11); two-tailed t-test; n = 6,6 animals), and TSLPR -/- animals (right; * p = 0.0357 ( t =2.696, df =6); two-tailed t-test; n = 4,4 animals. Skin homogenates were isolated on separate days and so uninjected, WT samples were not compared to aGr1-treated samples or to TSLPR -/- samples. G. (Left) Time spent scratching over a thirty minute interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back); (two-way ANOVA: **** p treatment < 0.0001, F(1,67) = 50.64; Tukey’s multiple comparisons: * p day 5 = 0.0216, n=8,10 mice; *** p day 8 = 0.0007, n=18,21 mice; **** p day 12 < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back), and immediately after mice were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 ( t =0.0964, df =8); two-tailed t-test; n = 5,5 mice. Values from bar plots in Figures 4F-G are displayed in Figure 4-source data 2 .

Article Snippet: CXCL10 protein was quantified using the Mouse CXCL10 Duoset ELISA kit (R&D Systems; #DY466-05) according to manufacturer’s instructions.

Techniques: Activity Assay, Staining, Two Tailed Test, Enzyme-linked Immunosorbent Assay, Isolation, Injection

A. AD induction first results in increased protease expression and barrier dysfunction, which drives production of the cytokines TSLP and CXCL1 via PAR2 activation within keratinocytes. CXCL1 can recruit neutrophils via its receptor CXCR2. Neutrophils may evoke itch by multiple pathways, including degranulation and release of proteases and histamine, production of sensitizing lipids such as PGE 2 and LTB 4 , 52 and induction of CXCL10 expression, which can activate sensory neurons via CXCR3. TSLP activates a number of immune cells to elicit IL-4 production, including basophils, which results in increased IL-4, recruitment of CD4 + T cells, and sensitization of neurons to promote itch later in the model.

Journal: bioRxiv

Article Title: Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis

doi: 10.1101/653873

Figure Lengend Snippet: A. AD induction first results in increased protease expression and barrier dysfunction, which drives production of the cytokines TSLP and CXCL1 via PAR2 activation within keratinocytes. CXCL1 can recruit neutrophils via its receptor CXCR2. Neutrophils may evoke itch by multiple pathways, including degranulation and release of proteases and histamine, production of sensitizing lipids such as PGE 2 and LTB 4 , 52 and induction of CXCL10 expression, which can activate sensory neurons via CXCR3. TSLP activates a number of immune cells to elicit IL-4 production, including basophils, which results in increased IL-4, recruitment of CD4 + T cells, and sensitization of neurons to promote itch later in the model.

Article Snippet: CXCL10 protein was quantified using the Mouse CXCL10 Duoset ELISA kit (R&D Systems; #DY466-05) according to manufacturer’s instructions.

Techniques: Expressing, Activation Assay